Wilson JM, Nikooienejad A, Robins DA, Roell WC, Riesmeyer JS, Haupt A, et al
If 10% of the target population (an estimated 360,000 people) uses Wegovy for a full year, that would amount to additional net Medicare Part D spending of $2.8 billion for one year for this one drug alone
FEBS Lett 1985;185:262-6
Macedonian J Med Sci
It is based on the native GIP sequence with modifications that enable cross-reactivity at the GLP-1 receptor, plus a C20 fatty diacid chain attached via a linker for albumin binding (half-life approximately 5 days)
We lead with our deep technical expertise, partnering closely with food and beverage companies to incorporate fiber, protein, sweeteners, and hydrocolloids to various food applicationsensuring flavor, taste, and mouthfeel are never compromised